Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro

Himmerich, Hubertus; Bartsch, Stefanie; Hamer, Hajo M.; Mergl, Roland; Schönherr, Jeremias; Petersein, Charlotte; Munzer, Alexander; Kirkby, Kenneth C.; Bauer, Katrin; Sack, Ulrich

doi:10.1016/j.jpsychires.2013.07.026

Cited by 88 publications

(74 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, another study showed that lamotrigine inhibited IL-2 and IL-6 secretion but not TNF-α secretion in human whole blood after stimulation with a combination of anti-CD3 and anti-CD40 antibodies (12). Therefore, the use of different stimulants could result in different immunomodulatory effects of lamotrigine.…”

Section: Effects Of Lamotrigine On Immune System Parameters In Vivomentioning

confidence: 99%

“…Cultures were maintained at 5 % CO 2 and 90-95 % humidity at 37 °C. The concentration range of lamotrigine (3-24 µg mL -1 ) was chosen on the basis of therapeutic concentrations used in humans and previous studies in mice (11,12,18). In addition, a concentration higher than the therapeutic range was also tested (48 µg mL -1 ).…”

Section: Cell Culturesmentioning

confidence: 99%

“…Several reports have shown that antiepileptic drugs cause alteration in the cellular and humoral immune responses, both in vitro and in vivo. In this context, most of the relevant data are focused on only a few classical antiepileptic agents, such as carbamazepine, phenytoin and valproate (10)(11)(12)(13). However, studies performed on newer antiepileptic drugs, such as lamotrigine, are rare and focused on in vitro testing (11)(12)(13).…”

mentioning

confidence: 99%

“…With regard to its immunomodulatory effects in epilepsy, low levels of immunoglobulins have been observed in the sera of epileptic patients treated with lamotrigine (16). In vitro, lamotrigine has been shown to inhibit IL-2, IL-1β and TNF-α secretion, but not IL-6 secretion, in stimulated-human whole blood (12), while it had no effect on murine splenocyte proliferation in vitro (11).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

et al. 2017

View full text Add to dashboard Cite

Modulation of the immune system has recently been shown to be involved in the pharmacological effects of old antiepileptic drugs and in the pathogenesis of epilepsy. Therefore, the most recent guidelines for immunotoxicological evaluation of drugs were consulted to investigate the immunomodulatory effects of lamotrigine, a newer antiepileptic drug, in BALB/c mice. These included the in vivo effects of lamotrigine on delayed-type hypersensitivity (DTH) response to sheep red blood cell (SRBC) antigens, hemagglutination titer assays and hematological changes. In vitro effects of lamotrigine on ConA-induced splenocyte proliferation and cytokine secretion were assessed. The results showed that lamotrigine treatment significantly increased the DTH response to SRBC in the mouse model of this study. This was accompanied by a significant increase in relative monocyte and neutrophil counts and in spleen cellularity. Lamotrigine significantly inhibited ConA-induced splenocyte proliferation in vitro and it significantly inhibited IL-2 and TNF-α secretion in ConA-stimulated splenocytes. In conclusion, the results demonstrated significant immunomodulatory effects of lamotrigine in BALB/c mice. These data could expand the understanding of lamotrigine-induced adverse reactions and its role in modulating the immune system in epilepsy.

show abstract

Section: Effects Of Lamotrigine On Immune System Parameters In Vivomentioning

confidence: 99%

Section: Cell Culturesmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All people with TLE were medicated, and AEDscould influence immune parameters. Most of these drug-related effects were anti-inflammatory or immunosuppressive,and people with TLE exhibited an enhanced inflammatoryimmune profiledespite the use of AEDs.For instance, there wasdecreasedsecretion of pro-inflammatory cytokines, especially IL-1β and TNF, in human PBMC cultivated withcarbamazepine, lamotrigine, oxcarbazepine, phenobarbital, topiramate, and valproate [39]. CD8 + T cells secreting perforin reduced degranulation after culture with valproate and levetiracetam [40].…”

Section: Inflammatory Association With Clinical Findingsmentioning

confidence: 99%

Peripheral leukocyte profile in people with temporal lobe epilepsy reflects the associated proinflammatory state

Vieira

Oliveira

Lessa

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications

Badary

2023

Reviews in Medical Virology

View full text Add to dashboard Cite

COVID‐19 was announced as a global pandemic in 2020. Several types of COVID‐19 vaccines are available such as mRNA vaccines, adenovirus vector vaccines, and protein subunit or inactivated virus vaccines. Vaccines are often administered in patients with chronic diseases who are likely to be treated with several drugs. A growing number of clinical observations indicated the possibility of interactions between COVID‐19 vaccines and drugs. A hyperinflammatory state may spark significant imbalances in drug metabolism that may result in the alteration of drug pharmacokinetics and therapeutic response. Furthermore, interactions may result in additive or antagonistic or synergistic vaccine immune response. Information about COVID‐19 vaccine–drug interactions is needed by physicians and pharmacists to make rational drug‐use decisions. In this review, several individual and categorical evidence‐based potential COVID‐19 vaccine–drug interactions of clinical importance are described. Vigilance is needed to detect previously unreported COVID‐19 drug interactions and to further assess known interactions. The clinical significance of which is not fully determined. Evidence suggests that adverse events to some drugs are rare after COVID‐19 vaccination and their possibility should not affect vaccination of patients at risk. Clinicians prescribing medications should be aware of the likely risk of interaction with COVID‐19 vaccines and may benefit from taking into account present recommendations of the best measures to avoid consequences of such interactions to preserve vaccine efficacy and patient safety.

show abstract

Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro

Cited by 88 publications

References 74 publications

Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

Peripheral leukocyte profile in people with temporal lobe epilepsy reflects the associated proinflammatory state

Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications

Contact Info

Product

Resources

About